110 related articles for article (PubMed ID: 36634548)
41. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.
Edelmann F; Holzendorf V; Wachter R; Nolte K; Schmidt AG; Kraigher-Krainer E; Duvinage A; Unkelbach I; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Stough WG; Pieske BM
Eur J Heart Fail; 2015 Feb; 17(2):214-23. PubMed ID: 25418979
[TBL] [Abstract][Full Text] [Related]
42. Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction.
Przewlocka-Kosmala M; Marwick TH; Mysiak A; Kosowski W; Kosmala W
Eur Heart J Cardiovasc Imaging; 2019 Oct; 20(10):1138-1146. PubMed ID: 31502637
[TBL] [Abstract][Full Text] [Related]
43. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
44. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
Gu J; Fan YQ; Han ZH; Fan L; Bian L; Zhang HL; Xu ZJ; Yin ZF; Xie YS; Zhang JF; Wang CQ
Int J Cardiol; 2016 Oct; 220():56-60. PubMed ID: 27372043
[TBL] [Abstract][Full Text] [Related]
45. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
Vizzardi E; D'Aloia A; Giubbini R; Bordonali T; Bugatti S; Pezzali N; Romeo A; Dei Cas A; Metra M; Dei Cas L
Am J Cardiol; 2010 Nov; 106(9):1292-6. PubMed ID: 21029826
[TBL] [Abstract][Full Text] [Related]
46. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
47. [Spironolactone not effective in diastolic heart failure].
Voors AA
Ned Tijdschr Geneeskd; 2014; 158():A7805. PubMed ID: 25004789
[TBL] [Abstract][Full Text] [Related]
48. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Ferreira JP; Collier T; Clark AL; Mamas MA; Rocca HB; Heymans S; González A; Ahmed FZ; Petutschnigg J; Mujaj B; Cuthbert J; Rouet P; Pellicori P; Mariottoni B; Cosmi F; Edelmann F; Thijs L; Staessen JA; Hazebroek M; Verdonschot J; Rossignol P; Girerd N; Cleland JG; Zannad F
Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):149-156. PubMed ID: 33822033
[TBL] [Abstract][Full Text] [Related]
49. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
[TBL] [Abstract][Full Text] [Related]
50. Provocation of masked left ventricular mechanical dyssynchrony by treadmill exercise in patients with systolic heart failure and narrow QRS complex.
Wang YC; Hwang JJ; Yu CC; Lai LP; Tsai CT; Lin LC; Katra R; Lin JL
Am J Cardiol; 2008 Mar; 101(5):658-61. PubMed ID: 18308016
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Implications of QRS Duration in Third-Degree Atrioventricular Block Patients with Heart Failure Treated with Cardiac Resynchronization Therapy.
Chen K; Su H; Xie C; Wang Q; Yu F; Sun Q; Zhu H; Yang D; Xu J; Yan J
Int Heart J; 2018 Nov; 59(6):1320-1326. PubMed ID: 30369567
[TBL] [Abstract][Full Text] [Related]
52. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
[TBL] [Abstract][Full Text] [Related]
53. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
[TBL] [Abstract][Full Text] [Related]
54. Is mechanical dyssynchrony a therapeutic target in heart failure with preserved ejection fraction?
Menet A; Greffe L; Ennezat PV; Delelis F; Guyomar Y; Castel AL; Guiot A; Graux P; Tribouilloy C; Marechaux S
Am Heart J; 2014 Dec; 168(6):909-16.e1. PubMed ID: 25458655
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
[TBL] [Abstract][Full Text] [Related]
56. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Cannon JA; Collier TJ; Shen L; Swedberg K; Krum H; Van Veldhuisen DJ; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
Eur J Heart Fail; 2015 Jul; 17(7):707-16. PubMed ID: 26139584
[TBL] [Abstract][Full Text] [Related]
57. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of mechanical dyssynchrony in patients with heart failure and preserved left ventricular function (a report from the Belgian Multicenter Registry on dyssynchrony).
De Sutter J; Van de Veire NR; Muyldermans L; De Backer T; Hoffer E; Vaerenberg M; Paelinck B; Decoodt P; Gabriel L; Gillebert TC; Van Camp G;
Am J Cardiol; 2005 Dec; 96(11):1543-8. PubMed ID: 16310437
[TBL] [Abstract][Full Text] [Related]
59. A prolonged QRS duration on surface electrocardiogram is a specific indicator of left ventricular dysfunction [see comment].
Murkofsky RL; Dangas G; Diamond JA; Mehta D; Schaffer A; Ambrose JA
J Am Coll Cardiol; 1998 Aug; 32(2):476-82. PubMed ID: 9708478
[TBL] [Abstract][Full Text] [Related]
60. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
